These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 8954952)
1. An anti-HIV peptide, T22, forms a highly active complex with Zn(II). Tamamura H; Otaka A; Murakami T; Ibuka T; Sakano K; Waki M; Matsumoto A; Yamamoto N; Fujii N Biochem Biophys Res Commun; 1996 Dec; 229(2):648-52. PubMed ID: 8954952 [TBL] [Abstract][Full Text] [Related]
2. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure. Tamamura H; Waki M; Imai M; Otaka A; Ibuka T; Waki K; Miyamoto K; Matsumoto A; Murakami T; Nakashima H; Yamamoto N; Fujii N Bioorg Med Chem; 1998 Apr; 6(4):473-9. PubMed ID: 9597190 [TBL] [Abstract][Full Text] [Related]
3. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240 [TBL] [Abstract][Full Text] [Related]
4. Interaction of an anti-HIV peptide, T22, with gp120 and CD4. Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026 [TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships of an anti-HIV peptide, T22. Tamamura H; Murakami T; Masuda M; Otaka A; Takada W; Ibuka T; Nakashima H; Waki M; Matsumoto A; Yamamoto N Biochem Biophys Res Commun; 1994 Dec; 205(3):1729-35. PubMed ID: 7811258 [TBL] [Abstract][Full Text] [Related]
6. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II). Tamamura H; Arakaki R; Funakoshi H; Imai M; Otaka A; Ibuka T; Nakashima H; Murakami T; Waki M; Matsumoto A; Yamamoto N; Fujii N Bioorg Med Chem; 1998 Feb; 6(2):231-8. PubMed ID: 9547946 [TBL] [Abstract][Full Text] [Related]
7. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule. Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Yamamoto N; Fujii N Biochem Biophys Res Commun; 1995 Oct; 215(2):626-31. PubMed ID: 7488001 [TBL] [Abstract][Full Text] [Related]
8. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance. Tamamura H; Ishihara T; Otaka A; Murakami T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N Biochim Biophys Acta; 1996 Nov; 1298(1):37-44. PubMed ID: 8948487 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. Tamamura H; Kuroda M; Masuda M; Otaka A; Funakoshi S; Nakashima H; Yamamoto N; Waki M; Matsumoto A; Lancelin JM Biochim Biophys Acta; 1993 May; 1163(2):209-16. PubMed ID: 8490053 [TBL] [Abstract][Full Text] [Related]
10. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II). Otaka A; Tamamura H; Terakawa Y; Masuda M; Koide T; Murakami T; Nakashima H; Matsuzaki K; Miyajima K; Ibuka T Biol Pharm Bull; 1994 Dec; 17(12):1669-72. PubMed ID: 7735216 [TBL] [Abstract][Full Text] [Related]
11. Femtomolar Zn(II) affinity in a peptide-based ligand designed to model thiolate-rich metalloprotein active sites. Petros AK; Reddi AR; Kennedy ML; Hyslop AG; Gibney BR Inorg Chem; 2006 Dec; 45(25):9941-58. PubMed ID: 17140191 [TBL] [Abstract][Full Text] [Related]
12. Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection. Tamamura H; Otaka A; Takada W; Terakawa Y; Yoshizawa H; Masuda M; Ibuka T; Murakami T; Nakashima H; Waki M Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):12-8. PubMed ID: 7895303 [TBL] [Abstract][Full Text] [Related]
13. Selective recognition of configurational substates of zinc cyclam by carboxylates: implications for the design and mechanism of action of anti-HIV agents. Liang X; Weishäupl M; Parkinson JA; Parsons S; McGregor PA; Sadler PJ Chemistry; 2003 Oct; 9(19):4709-17. PubMed ID: 14566877 [TBL] [Abstract][Full Text] [Related]
15. An antiparallel beta-sheet and a beta-turn characterize the structure of antiviral HIV-1 peptide T140, as revealed by 2D NMR and MD Simulations. Tauro S; Coutinho E; Srivastava S Protein Pept Lett; 2003 Aug; 10(4):346-60. PubMed ID: 14529488 [TBL] [Abstract][Full Text] [Related]
16. Selective bridging of bis-cysteinyl residues by arsonous acid derivatives as an approach to the characterization of protein tertiary structures and folding pathways by mass spectrometry. Happersberger HP; Przybylski M; Glocker MO Anal Biochem; 1998 Nov; 264(2):237-50. PubMed ID: 9866689 [TBL] [Abstract][Full Text] [Related]
17. Peptide-lead CXCR4 antagonists with high anti-HIV activity. Fujii N; Tamamura H Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804 [TBL] [Abstract][Full Text] [Related]
18. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Gustafson KR; Sowder RC; Henderson LE; Cardellina JH; McMahon JB; Rajamani U; Pannell LK; Boyd MR Biochem Biophys Res Commun; 1997 Sep; 238(1):223-8. PubMed ID: 9299483 [TBL] [Abstract][Full Text] [Related]
19. Electrospray-ionization mass spectrometry for the detection of discrete peptide/metal-ion complexes involving multiple cysteine (sulfur) ligands. Allen MH; Hutchens TW Rapid Commun Mass Spectrom; 1992 Apr; 6(4):308-12. PubMed ID: 1571599 [TBL] [Abstract][Full Text] [Related]
20. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Nakashima H; Masuda M; Murakami T; Koyanagi Y; Matsumoto A; Fujii N; Yamamoto N Antimicrob Agents Chemother; 1992 Jun; 36(6):1249-55. PubMed ID: 1384424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]